Lactobacillus GG in the Prevention of Nosocomial Gastrointestinal and Respiratory Tract Infections

Schematic diagram of the respiratory tract ant...Image via Wikipedia

  1. PEDIATRICS Vol. 125 No. 5 May 1, 2010 
    pp. e1171 -e1177 
    (doi: 10.1542/peds.2009-2568)
  1. » AbstractFree

  1. Iva Hojsak, MDa
  2. Slaven Abdović, MDa
  3. Hania Szajewska, MDb,
  4. Milan Milošević, MDc
  5. Željko Krznarić, MD, PhDd
  6. Sanja Kolaček, MD, PhDa
+Author Affiliations

  1. aReferral Center for Pediatric Gastroenterology and Nutrition, Children’s Hospital Zagreb, Klaićeva 16, Zagreb, Croatia;

  2. b2nd Department of Pediatrics, Medical University of Warsaw, Warsaw, Poland;

  3. cDepartment for Environmental and Occupational Health, “Andrija Štampar” School of Public Health, Rockefellerova 4, Zagreb, Croatia; and

  4. dDivision of Gastroenterology and Hepatology, University Hospital Center Zagreb, Kispaticeva 12, Zagreb, Croatia


OBJECTIVE: The incidence of nosocomial infections, predominantly gastrointestinal and respiratory, in children in developed countries is high, ranging from 5% to 44%. There is no effective strategy for preventing these infections. The objective of our study was to investigate the role ofLactobacillusGG (LGG) in preventing nosocomial gastrointestinal and respiratory tract infections at a pediatric hospital.
METHODS: We conducted a randomized, double-blind, placebo-controlled trial of 742 hospitalized children. They were randomly allocated to receive for their hospitalization LGG at a dose of 109 colony-forming units in 100 mL of a fermented milk product (LGG group, n = 376) or placebo that was the same postpasteurized fermented milk product without LGG (placebo group, n = 366).
RESULTS: In the LGG group, compared with the placebo group, we found a significantly reduced risk for gastrointestinal infections (relative risk [RR]: 0.40 [95% confidence interval (CI): 0.25–0.70]; number needed to treat: 15 [95% CI: 9–34)], respiratory tract infections (RR: 0.38 [95% CI: 0.18–0.85]; number needed to treat: 30 [95% CI: 16–159]), vomiting episodes (RR: 0.5 [95% CI: 0.3–0.9]), diarrheal episodes (RR: 0.24 [95% CI: 0.10–0.50]), episodes of gastrointestinal infections that lasted >2 days (RR: 0.40 [95% CI: 0.25–0.70]), and episodes of respiratory tract infections that lasted >3 days (RR: 0.4 [95% CI: 0.2–0.9]). Groups did not differ in hospitalization duration (P = .1).
CONCLUSIONS: LGG administration can be recommended as a valid measure for decreasing the risk for nosocomial gastrointestinal and respiratory tract infections in pediatric facilities.

This entry was posted in bacteria, Conditions and Diseases, Genitourinary Disorders, Health, Lactobacillus, Probiotic, Respiratory Tract, Urinary tract infection. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s